Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma.
Shapiro
Michael
M
Department of Dermatology, University of Pennsylvania, Philadelphia, USA.
Rook
Alain H
AH
Lehrer
Michael S
MS
Junkins-Hopkins
Jacqueline M
JM
French
Lars E
LE
Vittorio
Carmela C
CC
D000077610:Bexarotene; D001707:Biopsy, Needle; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D007155:Immunologic Factors / Q000627:therapeutic use*; D016410:Lymphoma, T-Cell, Cutaneous / Q000473:pathology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012878:Skin Neoplasms / Q000473:pathology* / Q000628:therapy*; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*; D016896:Treatment Outcome; D014467:Ultraviolet Therapy / Q000379:methods*
D007155:Immunologic Factors; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene